PCSA Processa Pharmaceuticals Inc

Price (delayed)

$1.89

Market cap

$5.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.39

Enterprise value

$5.08M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies ...

Highlights
PCSA's debt has dropped by 100% year-on-year
The EPS has soared by 92% YoY and by 54% from the previous quarter
PCSA's net income is up by 4.7% QoQ but it is down by 4.3% YoY
Processa Pharmaceuticals's equity has shrunk by 112% QoQ and by 105% YoY
Processa Pharmaceuticals's quick ratio has shrunk by 92% YoY and by 67% QoQ

Key stats

What are the main financial stats of PCSA

PCSA stock price

How has the Processa Pharmaceuticals stock price performed over time
Intraday
0.53%
1 week
2.16%
1 month
-9.13%
1 year
-64.74%
YTD
-34.38%
QTD
-1.56%

Financial performance

How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.89M
Net income
-$13.44M
Gross margin
N/A
Net margin
N/A
Processa Pharmaceuticals's operating income has increased by 11% QoQ
PCSA's net income is up by 4.7% QoQ but it is down by 4.3% YoY

Price vs fundamentals

How does PCSA's price correlate with its fundamentals

Growth

What is Processa Pharmaceuticals's growth rate over time

Valuation

What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 92% YoY and by 54% from the previous quarter
Processa Pharmaceuticals's equity has shrunk by 112% QoQ and by 105% YoY

Efficiency

How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on equity has decreased by 40% QoQ and by 15% YoY
The ROA has contracted by 22% from the previous quarter

Dividends

What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCSA.

Financial health

How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's total assets is 13% lower than its total liabilities
Processa Pharmaceuticals's quick ratio has shrunk by 92% YoY and by 67% QoQ
Processa Pharmaceuticals's total assets has shrunk by 75% YoY and by 54% QoQ
PCSA's debt is 100% greater than its equity
Processa Pharmaceuticals's equity has shrunk by 112% QoQ and by 105% YoY
PCSA's debt has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.